chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Myalgia, Pyrexia
Clinical narrative: Fever; chills; muscle pain; This is a spontaneous report from a contactable physician, the patient. A 44-years-old adult non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the arm left on 31Mar2021 at 10:30 (at the age of 44-years-old) as a dose number unknown, single for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. Concomitant medications were not reported. On 01Apr2021, at 01:00, the patient experienced fever, chills and muscle pain. The patient did not receive any treatment for the event. The adverse event did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. The clinical outcome of the event Fever, chills and muscle pain was unknown.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.  Amendment: This follow-up report is being submitted to amend previously reported information: Vaccination Facility Country added UNITED STATES. Narrative "The patient did not receive any medication within two weeks of vaccination." and "The patient did not receive any other vaccines within four weeks prior to the vaccination." removed.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Diarrhoea, Headache, Malaise, Oropharyngeal pain
Clinical narrative: Sore throat; Vomiting; Diarrhea; Headache; Chills; Malaise; This is a spontaneous report from a contactable consumer, the patient. A 50-year-old, non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the arm left on 01Apr2021 at 16:00 (at the age of 50-year-old) as a single dose for COVID-19 immunisation. Medical history was reported as none. The patient did not have any allergies to medications, food, or other products. Concomitant medications were not reported. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 02Apr2021 at 16:00, the patient experienced vomiting, diarrhea, sore throat, headache, chills and malaise. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events vomiting, diarrhea, sore throat, headache, chills and malaise were not resolved at the time of reporting.  No follow-up attempts are needed; information about lot number cannot be obtained.  Amendment: This follow-up report is being submitted to amend previously reported information:Relevant Med History None added.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Vomiting
Clinical narrative: Sore throat; Vomiting; Diarrhea; Headache; Chills; Malaise; This is a spontaneous report from a contactable consumer, the patient. A 50-year-old, non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the arm left on 01Apr2021 at 16:00 (at the age of 50-year-old) as a single dose for COVID-19 immunisation. Medical history was reported as none. The patient did not have any allergies to medications, food, or other products. Concomitant medications were not reported. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 02Apr2021 at 16:00, the patient experienced vomiting, diarrhea, sore throat, headache, chills and malaise. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events vomiting, diarrhea, sore throat, headache, chills and malaise were not resolved at the time of reporting.  No follow-up attempts are needed; information about lot number cannot be obtained.  Amendment: This follow-up report is being submitted to amend previously reported information:Relevant Med History None added.
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Swelling
Clinical narrative: Swollen arm pit; This is a spontaneous report from a non-contactable consumer, the patient. A 34-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 02Apr2021 (at the age of 34-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medication were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 03Apr2021, on the 2nd day after 1st dose, the patient experienced swollen arm pit that lasted around 5 days. The clinical outcome of the event swollen arm pit was recovering at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Dysmenorrhoea, Heavy menstrual bleeding, Polymenorrhoea, Premenstrual syndrome
Clinical narrative: After the first dose, next period came 11+ days early; Period lasted eight days; PMS equal to or stronger than normal; Cramping equal to or stronger than normal; This is a spontaneous report from a contactable consumer, the patient. A 35-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6203) via an unspecified route of administration in the left arm on 24Feb2021 at 14:00 (at the age of 35-year-old) as a single dose and the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7534) via an unspecified route of administration in the left arm on 17Mar2021 at 13:30 (at the age of 35-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medications included gabapentin (MANUFACTURER UNKNOWN) for an unknown indication from an unknown date. The patient previously took erythromycin (MANUFACTURER UNKNOWN) and codeine (MANUFACTURER UNKNOWN); both for an unknown indication from an unknown date and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 10Mar2021, after the first dose, the patient's next period came 11+ days early and lasted eight days. The typical cycle, for the patient, was 28-30 days with menstruation lasting about three days. The patient also experienced premenstrual syndrome (PMS) and cramping that were also equal to or stronger than normal, both of which were typically strong, to begin with. After the second dose, the period came 8 plus days early with similar symptoms to the last, though not lasting as long. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department, or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the event after the first dose next period came 11+ days early, period lasted eight days, PMS equal to or stronger than normal, and cramping equal to or stronger than normal was unknown at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Infection parasitic
Clinical narrative: I have Parasites inside my blood street some are small and some are much bigger; This is a spontaneous report from a contactable other healthcare professional, the patient. A 50-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8727) via an unspecified route of administration in the left arm on 23Mar2021 at 17:45 (at the age of 50-years-old) as a single dose for COVID-19 immunisation. Medical history included acid reflux and two hernias. Concomitant medications included calcium carbonate (TUMS), aluminum hydroxide; magnesium hydroxide; simeticone  (MYLANTA) and simeticone (GAS X); all from unknown dates for unknown indications. The patient had no known allergies to medications, food, or other products. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 02Mar2021 at 17:30 (at the age of 50-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 28Mar2021 at 02:30, the patient reported that she had parasites inside her blood stream (street) some are small and some are much bigger. The event resulted in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. No therapeutic measures were taken for the reported event. The clinical outcome of the event parasites inside blood street some are small and some are much bigger was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Feeling of body temperature change, Headache, Influenza like illness, Nausea, Pain
Clinical narrative: Flu like symptoms; Body aches; Hot and cold; Nausea; Headache; This is a spontaneous report from a contactable consumer, the patient. A 61-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the left arm on 31Mar2021 at 13:00 (at the age of 61-year-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 06Apr2021 at 13:00, the patient experienced flu like symptoms, body aches, headache, hot and cold and nausea. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of the event flu like symptoms, body aches, headache, hot and cold and nausea were recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 61.0
Sex: M
Vaccine: COVID19
Symptoms: Dry eye, Facial discomfort, Headache, Neck pain
Clinical narrative: Severe headache on the left side of my head; Pain on the left side of my neck.; feeling of dryness in the eye; Slight feeling of uneasiness on my left side of face; This is a spontaneous report from a contactable consumer, the patient. A 61-year-old male patient received the unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7534) via an unspecified route of administration on 28Mar2021 (at the age of 61-year-old) as a single dose for COVID-19 immunisation. Medical history included hypertension. The patient received unspecified medication within two weeks prior to vaccination. The patient was allergic to amoxicillin. Prior to vaccination, it was unknown whether the patient was diagnosed with COVID-19. Since the vaccination, it was unknown whether the patient had been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 29Mar2021, the patient experienced severe headache on the left side of head with pain on the left side of neck, slight feeling of uneasiness on left side of face along with feeling of dryness in the eye. Therapeutic measures were not taken as a result of the events. The events resulted in doctor or other healthcare professional office/clinic visit. The clinical outcome of the event severe headache, neck pain, dryness in the eye and facial discomfort was not recovered at the time of the report.  No follow-up attempts are needed. No further information is expected.
Age: 61.0
Sex: M
Vaccine: COVID19
Symptoms: Lymphadenopathy, Oropharyngeal pain
Clinical narrative: Persistent sore throat; Swollen lymph nodes (neck); This is a spontaneous report from a contactable consumer, the patient. A 61-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 22Mar2021 at 09:45 (at the age of 61-years-old) as a single dose for COVID-19 immunisation. The patient had no relevant medical history. The patient had no  known allergies to food, medications, or other products. Concomitant medications included levothyroxine (MANUFACTURER UNKNOWN) and pravastatin (MANUFACTURER UNKNOWN). The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19.  On 24Mar2021, the patient experienced swollen lymph nodes in the neck and persistent sore throat which was there for 1 week. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the event persistent sore throat and swollen lymph nodes in the neck were resolving at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Burning sensation, Chest discomfort, Dizziness, Dysgeusia, Dyspnoea
Clinical narrative: Dizziness; Metallic taste in mouth; Shortness of breath; Hot flushing sensation in torso and up the spine; Numbness on hands; Numbness on lowerlegs; Numbness in leg; Heaviness or thickness feeling of the tongue; Throat tightness; Chest heaviness; Irregular pulse; Difficulty in moving muscles; Burning armpits; This is a spontaneous report from a contactable consumer, the patient. A 50-years-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration in the right arm on 06Apr2021 at 00:15, (at the age of 50-years-old) as a single dose for COVID-19immunisation. Medical history included asthma, osteoarthritis, depression, penicillin allergy, brazil nuts allergy and drug allergy (protonix, aspirin and levaquin). The patient had no known allergies to food, medicines or other products. Concomitant medications included prozac (MANUFACTURER UNKNOWN) and meloxicam (MANUFACTURER UNKNOWN) for unknown indication, on an unknown date. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 06Apr2021 at 12:45 the patient experienced dizziness, metallic taste in mouth, shortness of breath, hot flushing sensation in torso and up the spine, burning armpits, numbness of the face hands and lower legs, heaviness/ thick feeling of the tongue, throat tightness chest heaviness and irregular pulse. On 06Apr2021, the patient  experienced irregular pulse rate 80-145 and oxygen dropped to 88 percent and after 5 hours the pulse rate was 96 and oxygen saturation improved to 92. No therapeutic measures were taken as a result of reported event. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event throat tightness, chest heaviness, dizziness, metallic taste in mouth, shortness of breath, hot flushing sensation in torso and up the spine, burning armpits, numbness of the face hands and lower legs, heaviness/ thick feeling of the tongue, irregular pulse and difficulty in moving muscles was recovering.  No follow-up attempts are needed. No further information is expected.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Heart rate, Heart rate irregular, Hot flush, Hypoaesthesia, Muscle disorder
Clinical narrative: Dizziness; Metallic taste in mouth; Shortness of breath; Hot flushing sensation in torso and up the spine; Numbness on hands; Numbness on lowerlegs; Numbness in leg; Heaviness or thickness feeling of the tongue; Throat tightness; Chest heaviness; Irregular pulse; Difficulty in moving muscles; Burning armpits; This is a spontaneous report from a contactable consumer, the patient. A 50-years-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration in the right arm on 06Apr2021 at 00:15, (at the age of 50-years-old) as a single dose for COVID-19immunisation. Medical history included asthma, osteoarthritis, depression, penicillin allergy, brazil nuts allergy and drug allergy (protonix, aspirin and levaquin). The patient had no known allergies to food, medicines or other products. Concomitant medications included prozac (MANUFACTURER UNKNOWN) and meloxicam (MANUFACTURER UNKNOWN) for unknown indication, on an unknown date. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 06Apr2021 at 12:45 the patient experienced dizziness, metallic taste in mouth, shortness of breath, hot flushing sensation in torso and up the spine, burning armpits, numbness of the face hands and lower legs, heaviness/ thick feeling of the tongue, throat tightness chest heaviness and irregular pulse. On 06Apr2021, the patient  experienced irregular pulse rate 80-145 and oxygen dropped to 88 percent and after 5 hours the pulse rate was 96 and oxygen saturation improved to 92. No therapeutic measures were taken as a result of reported event. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event throat tightness, chest heaviness, dizziness, metallic taste in mouth, shortness of breath, hot flushing sensation in torso and up the spine, burning armpits, numbness of the face hands and lower legs, heaviness/ thick feeling of the tongue, irregular pulse and difficulty in moving muscles was recovering.  No follow-up attempts are needed. No further information is expected.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Oxygen saturation, Throat tightness, Tongue disorder
Clinical narrative: Dizziness; Metallic taste in mouth; Shortness of breath; Hot flushing sensation in torso and up the spine; Numbness on hands; Numbness on lowerlegs; Numbness in leg; Heaviness or thickness feeling of the tongue; Throat tightness; Chest heaviness; Irregular pulse; Difficulty in moving muscles; Burning armpits; This is a spontaneous report from a contactable consumer, the patient. A 50-years-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration in the right arm on 06Apr2021 at 00:15, (at the age of 50-years-old) as a single dose for COVID-19immunisation. Medical history included asthma, osteoarthritis, depression, penicillin allergy, brazil nuts allergy and drug allergy (protonix, aspirin and levaquin). The patient had no known allergies to food, medicines or other products. Concomitant medications included prozac (MANUFACTURER UNKNOWN) and meloxicam (MANUFACTURER UNKNOWN) for unknown indication, on an unknown date. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 06Apr2021 at 12:45 the patient experienced dizziness, metallic taste in mouth, shortness of breath, hot flushing sensation in torso and up the spine, burning armpits, numbness of the face hands and lower legs, heaviness/ thick feeling of the tongue, throat tightness chest heaviness and irregular pulse. On 06Apr2021, the patient  experienced irregular pulse rate 80-145 and oxygen dropped to 88 percent and after 5 hours the pulse rate was 96 and oxygen saturation improved to 92. No therapeutic measures were taken as a result of reported event. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event throat tightness, chest heaviness, dizziness, metallic taste in mouth, shortness of breath, hot flushing sensation in torso and up the spine, burning armpits, numbness of the face hands and lower legs, heaviness/ thick feeling of the tongue, irregular pulse and difficulty in moving muscles was recovering.  No follow-up attempts are needed. No further information is expected.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Erythema, Vaccination site erythema, Vaccination site pain
Clinical narrative: Injection site reddened  that extended to the elbow; Injection site reddened; injection site burning; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8729) via an unspecified route of administration in the left arm on 06Apr2021 at 18:45 (at the age of 52-years-old) as a single dose for COVID-19 immunisation. Medical history included sulfa, iodine and alcohol allergy. Concomitant medications included cetirizine hydrochloride (ZYRTEK) from unknown date for unspecified indication and unknown if ongoing. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 06Apr2021 at 18:45, the patient experienced injection site reddened that extended to the elbow and injection site burning. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the events which included treatment with 50 mg benadryl (MANUFACTURER UNKNOWN). The clinical outcome of events injection site reddened that extended to the elbow and injection site burning was resolved on an unknown date in Apr2021.    No follow-up attempts are needed. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Diarrhoea, Eructation, Nausea, Pain
Clinical narrative: Fever; chills; body aches; nausea; burping; Diarrhea; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6207) via an unspecified route of administration in the arm left on 06Apr2021 at 09:00 (at the age of 37-year-old) as a single dose for COVID-19 immunisation. Medical history included High Blood Pressure.  The patient had no known allergies to medications, food, or other products. The concomitant medications included Atenolol (MANUFACTURER UNKNOWN)from unknown date for unknown indication taken within 2 weeks of vaccination. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6199) via an unspecified route of administration in the arm left on 15Mar2021 at 17:15 (at the age of 37-year-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 06Apr2021 the patient experienced Fever, Chills, Body Aches, Nausea, Burping and Diarrhea. No therapeutic measures were taken as a result of the event. The clinical outcome of the events Fever, Chills, Body Aches, Nausea, Burping and Diarrhea were not resolved at the time of the report.  No follow-up attempts are needed. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: Fever; chills; body aches; nausea; burping; Diarrhea; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6207) via an unspecified route of administration in the arm left on 06Apr2021 at 09:00 (at the age of 37-year-old) as a single dose for COVID-19 immunisation. Medical history included High Blood Pressure.  The patient had no known allergies to medications, food, or other products. The concomitant medications included Atenolol (MANUFACTURER UNKNOWN)from unknown date for unknown indication taken within 2 weeks of vaccination. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6199) via an unspecified route of administration in the arm left on 15Mar2021 at 17:15 (at the age of 37-year-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 06Apr2021 the patient experienced Fever, Chills, Body Aches, Nausea, Burping and Diarrhea. No therapeutic measures were taken as a result of the event. The clinical outcome of the events Fever, Chills, Body Aches, Nausea, Burping and Diarrhea were not resolved at the time of the report.  No follow-up attempts are needed. No further information is expected.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Decreased appetite, Fatigue, Pain, Pyrexia
Clinical narrative: Fatigue; Chills; Fever; Body aches; Loss of appetite; This is a spontaneous report from a contactable consumer, the patient. A 50-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733) via an unspecified route of administration in the right arm on 31Mar2021 at 08:30 (at the age of 50-year-old) as a single dose for COVID-19 immunisation. Medical history included bipolar disorder. Concomitant medications included lithium (MANUFACTURER UNKNOWN) and risperidone (MANUFACTURER UNKNOWN). The patient had no known allergies. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 02Apr2021 the patient experienced fatigue, chills, fever, body aches and loss of appetite. The events resulted in doctor or other healthcare professional office/clinic visit. No therapeutic measures were taken as a result of the events. The clinical outcome of the events fatigue, chills, fever, body aches and loss of appetite was recovered on an unknown date in 2021.   No follow-up attempts are needed. No further information is expected.
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Lymphadenopathy
Clinical narrative: Swollen lymph node in left armpit; This is a spontaneous report from a contactable consumer, the patient. A 47-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER 8732) via an unspecified route of administration in the left arm on 31Mar2021 at 12:00 (at the age of 47-year-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient previously took Septra and experienced allergy. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN 6208) via an unspecified route of administration in the left arm on 10Mar2021 at 12:00 (at the age of 47-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 01Apr2021 at 19:00 the patient experienced swollen lymph node in left armpit for at least one week. The patient did not receive any treatment for the event. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event swollen lymph node in left armpit for at least one week was unknown at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Asthma, Chest discomfort, Wheezing
Clinical narrative: Asthma attack which is not a normal experience; Wheezing continues; chest still feels tight; This is a spontaneous report from a contactable consumer, the patient. A 47-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 05Apr2021 at 09:30 (at the age of 47-year-old) as a single dose for COVID-19 immunisation. Medical history included asthma. The patient was allergic to sulfonamide (sulfa) and latex. Concomitant medications included fluticasone propionate and salmeterol xinafoate (ADVAIR) 250/50, cetirizine hydrochloride (ZYRTEC) and vitamin B12  (MANUFACTURER UNKNOWN); all from unknown dates for unknown indications. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 07Apr2021 at 03:00, the patient experienced asthmatic attack, tightness in chest and wheezing. Its reported that, early morning, 3 a.m., of 07Apr2021, patient woke up to an asthma attack which was not a normal experience. Her chest still feels tight and wheezing continues. Her controller meds had kept from having any sort of attack since 2003. Therapeutic measures were taken as a result of reported events and included treatment with controller/rescue inhaler. The events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or  urgent care. The clinical outcome of the event of asthmatic attack  was recovering at the time of this report. The clinical outcome of the events of  wheezing and tightness in chest was not recovered at the time of this report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 32.0
Sex: F
Vaccine: COVID19
Symptoms: Dysmenorrhoea, Heavy menstrual bleeding, Menstruation delayed, SARS-CoV-2 test
Clinical narrative: Late mentsruation (1.5 weeks past due); Heavy flow; Heavy cramps and long lasting cramps; This is a spontaneous report from a contactable consumer, the patient. A 32-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: EN6202) via an unspecified route of administration in the arm left on 11Mar2021 at 11:45 (at the age of 32-year-old) as a single dose for COVID-19 immunisation. Medical history included fibromyalgia, spinal cord injury, joint and nerve damage/illness. The patient had latex and iodine allergy. Concomitant medications included lamotrigine (MANUFACTURER UNKNOWN) and hydrocodone bitartrate, paracetamol (NORCO) from unknown dates and for unknown indication. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On 22Mar2021, the patient experienced late menstruation (1.5 weeks past due), heavy flow, heavy cramps and long-lasting cramps. It was 2 weeks after her flow and still cramping at the time of this report. The patient did not receive any treatment for the reported events. The adverse events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. On 25Mar2021, the patient underwent rapid test (SASRs-CoV-2 test) and the result was negative. The clinical outcome of the event late menstruation (1.5 weeks past due) and heavy flow was unknown, while that of heavy cramps were not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Pruritus, Rash
Clinical narrative: rash; itching on arms, hands and legs; This is a spontaneous report from a contactable consumer, the patient. A 51-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on an unknown date in Mar2021 at 15:00 (at the age of 51-years-old) as a single dose for COVID-19 immunisation. Medical history included allergy to penicillin. The patient was allergic to tetracycline (MANUFACTURER UNKNOWN). Concomitant medications included lisinopril (MANUFACTURER UNKNOWN) and escitalopram (MANUFACTURER UNKNOWN); all for unknown indication and unknown start date. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 02Apr2021, the patient experienced rash and severe itching on arms, hands and legs. Therapeutic measures were not taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the event rash and itching were not resolved.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 46.0
Sex: F
Vaccine: COVID19
Symptoms: Herpes zoster, Lymphadenopathy
Clinical narrative: Shingles on the left side of my face; Enlarged Cervical Lymph Nodes; This is a spontaneous report from a contactable consumer, the patient. A 46-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 04Apr2021 at 16:15 (at the age of 46-years-old) as a single dose for COVID-19 immunisation. The patient medical history and concomitant medications was not provided. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 05Apr2021 at 08:00, the patient experienced shingles on the left side of her face and enlarged cervical lymph. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of events and included treatment with valacyclov and ibuprofen 800 mg from unknown date for an unknown indication. The clinical outcome of the events shingles on the left side of my face and enlarged cervical lymph were not recovered at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 67.0
Sex: M
Vaccine: COVID19
Symptoms: Tinnitus
Clinical narrative: Tinnitus; This is a spontaneous report from a contactable consumer, the patient. A 67-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: en6204) via an unspecified route of administration in the left arm on 03Mar2021 at 08:00 (at the age of 67-years-old) as a single dose for COVID-19 immunisation. The patient medical history included allergic to iodine. Patient received unspecified medications within 2 weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. Patient did not receive any other vaccine within 4 weeks prior to COVID vaccine.  On 04Mar2021, the patient experienced tinnitus. The adverse event did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. The patient did not receive any treatment for the event. The clinical outcome of the event tinnitus was not recovered at the time of reporting. Patient also received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ep6955) via an unspecified route of administration in the left arm on 24Mar2021 (at the age of 67-years-old) as a single dose for COVID-19 immunisation.  No follow-up attempts are needed. No further information is expected.
Age: 65.0
Sex: M
Vaccine: COVID19
Symptoms: Blood glucose, Blood glucose increased
Clinical narrative: elevated blood glucose levels about 210; This is a spontaneous report from a contactable consumer, the patient. A 65-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6198) via an unspecified route of administration in the left arm on 15Mar2021 at 12:00(at the age of 65-year-old) as a single dose for COVID-19 immunisation. Medical history included depression and type 2 diabetes mellitus. The patient received unspecified medication within 2 weeks of vaccination. The patient had allergies to unknown medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient underwent blood glucose test on unknown date and the result was 210 unknown unit. On 17Mar2021 at 00:00 the patient experienced elevated blood glucose levels about 210 for 3 weeks. No therapeutic measures were taken as a result of the event. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event elevated blood glucose levels about 210 was recovering at the time of report.   No follow-up attempts are needed. No further information is expected.
Age: 54.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Bed rest, Chills, Fatigue, Feeding disorder
Clinical narrative: I got the shot on Sunday; by Tuesday I was extremely nauseous.; . I was out of work for the rest of the week,; I sometimes felt on the verge of chills but never got really to the point where I was shaking.; A day after the injection I started to feel badly.; It was hard to eat much at all; I was only able to be in bed and sometimes sleep.; And I was tired. (I never threw up, never ran a fever, etc.); This is a spontaneous report from a contactable consumer, the patient. A 54-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: ER8703) via an unspecified route of administration in the left arm on 28Mar2021 at 03:30 (at the age of 54-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported.  Concomitant medications included varicella zoster vaccine rgE (cho) (SHINGRIX) from 09Mar2021 for unknown indication and escitalopram oxalate (LEXAPRO) for an unknown indication taken within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. The patient did receive other vaccines within four weeks prior to the vaccination. On 29Mar2021 at 09:00 a day after the injection, the patient started to feel badly, the patient got her shot on sunday and by tuesday on 30Mar2021, the patient was extremely nauseous and ran out of work for the rest of the week. On 29Mar2021 at 09:00, the patient was only able to be in bed and was sometimes sleepy. It was hard to eat much at all and the patient was tired (but never threw up, never ran a fever, etc). The patient sometimes felt on the verge of chills but never got really to the point where the patient was shaking. The nausea was very bad each day until about 5 pm - the evening were better. The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of adverse events and included treatment dramamine from an unspecified date. On 31Mar2021, the patient underwent saliva test for COVID-19 virus test and the result was found to be negative. The clinical outcome of the events, weak and a bit tired was not recovered even on the date of reporting on 07Apr2021, while that of  feeling bad, unable to eat, extremely nauseous, unable to be on bed, sleepy, chills were recovering at the time of this report.    No follow-up attempts are needed. No further information is expected.
Age: 54.0
Sex: F
Vaccine: COVID19
Symptoms: Feeling abnormal, Nausea, Saliva analysis
Clinical narrative: I got the shot on Sunday; by Tuesday I was extremely nauseous.; . I was out of work for the rest of the week,; I sometimes felt on the verge of chills but never got really to the point where I was shaking.; A day after the injection I started to feel badly.; It was hard to eat much at all; I was only able to be in bed and sometimes sleep.; And I was tired. (I never threw up, never ran a fever, etc.); This is a spontaneous report from a contactable consumer, the patient. A 54-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: ER8703) via an unspecified route of administration in the left arm on 28Mar2021 at 03:30 (at the age of 54-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported.  Concomitant medications included varicella zoster vaccine rgE (cho) (SHINGRIX) from 09Mar2021 for unknown indication and escitalopram oxalate (LEXAPRO) for an unknown indication taken within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. The patient did receive other vaccines within four weeks prior to the vaccination. On 29Mar2021 at 09:00 a day after the injection, the patient started to feel badly, the patient got her shot on sunday and by tuesday on 30Mar2021, the patient was extremely nauseous and ran out of work for the rest of the week. On 29Mar2021 at 09:00, the patient was only able to be in bed and was sometimes sleepy. It was hard to eat much at all and the patient was tired (but never threw up, never ran a fever, etc). The patient sometimes felt on the verge of chills but never got really to the point where the patient was shaking. The nausea was very bad each day until about 5 pm - the evening were better. The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of adverse events and included treatment dramamine from an unspecified date. On 31Mar2021, the patient underwent saliva test for COVID-19 virus test and the result was found to be negative. The clinical outcome of the events, weak and a bit tired was not recovered even on the date of reporting on 07Apr2021, while that of  feeling bad, unable to eat, extremely nauseous, unable to be on bed, sleepy, chills were recovering at the time of this report.    No follow-up attempts are needed. No further information is expected.
Age: 59.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Nausea
Clinical narrative: Headache; Nausea; Fatigue; This is a spontaneous report from a contactable consumer, the patient. A 59-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 02Apr2021 at 11:30 (at the age of 59-years-old), as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient did not have any allergies to medications, food, or other products. Concomitant medications included escitalopram (MANUFACTURER UNKNOWN), valacyclovir (MANUFACTURER UNKNOWN), zolmitriptan (MANUFACTURER UNKNOWN) and fish oil (MANUFACTURER UNKNOWN), all taken for unknown indications from unknown dates. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 03Apr2021 at 07:00, the patient experienced headache with nausea and fatigue. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of the events headache with nausea and fatigue was resolved on an unknown date in Apr2021.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 18.0
Sex: M
Vaccine: COVID19
Symptoms: Fatigue, Headache, Nasopharyngitis
Clinical narrative: headache; tired; cold; This is a spontaneous report from a contactable consumer, the patient. An 18-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8729) via an unspecified route of administration in the left arm on 07Apr2021 at 09:15 (at the age of 18-years-old) as a single dose for COVID-19 immunisation. Medical history included dermatographia. The patient had no allergies to medications, food, or other products. Concomitant medications included testosterone (MANUFACTURER UNKNOWN), quetiapine (MANUFACTURER UNKNOWN), dextroamphetamine (MANUFACTURER UNKNOWN) and lamotrigine (MANUFACTURER UNKNOWN), all taken for unknown indications from unknown dates. The patient previously received influenza vaccine (FLUZONE; Lot number: UT7115KA) in the right arm and meningococcal vaccine b (SANOFI PASTEUR; Lot number: U6586AA) in the left arm, both taken on 24Mar2021 for immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 07Apr2021 at 11:00, the patient experienced headache, cold and tiredness. The events did not result in doctor or other health care professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of the events headache, cold and tiredness was resolving at the time of this report.  No follow-up attempts are needed. No further information is expected.